New
Delfi Diagnostics
The AI engine Fit Assessment
BetaThe company will be attending ViVE 2025 Event
Blurb
Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.
HQ Location
Baltimore (United States)
Founded
2019
Employees
51 - 200
Total funding raised
$330.50M
Last Funding Event
Series B, $225.00M, July 18, 2022
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.